During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, and oral tablets containing tenofovir or a combination of tenofovir and emtricitabine known by the brand name Truvada.
Innovative approaches can help find vulnerable young women in need of HIV prevention services The following is a guest post by Michelle Li, MS, and Quinn […]
In the six weeks before South Africa responded its first diagnoses of COVID-19 with the start of physical distancing measures, more than 47,000 people on average […]
CDC urges physicians, parents to be on lookout for AFM, a polio-like illness seen predominately in children
With 2018 data showing highest incidence acute flaccid myelitis since monitoring began, officials say awareness, recognition of rare life threatening condition will be crucial to early […]
By Karen Carvajal, M.D. Over the course of human history we have come a long way in our fight against the threat of infectious diseases and, […]